Tag Archives: glioma

November, 2018

16 November
Agios Presents Updated Data from Phase 1 Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma

NEW ORLEANS, Nov. 16, 2018 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the ongoing Phase 1 study evaluating single agent AG-881 in advanced glioma. The data were featured in an …
Share

7 February
GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study

London, UK, 7 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination …
Share

7 December
Researchers Find New Biomarker for Brain Cancer Prognosis

DALLAS – Dec. 6, 2016 – Researchers at UT Southwestern Medical Center have found a new biomarker for glioma, a common type of brain cancer, that can help doctors determine how aggressive a cancer is and that could eventually help determine the best course of treatment. Researchers from the Harold …
Share

18 July
Ziopharm Reports Patient’s Death in Gene Therapy Trial for Patients with Brain Cancer

BOSTON, July 15, 2016 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding the Company’s ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma: “This Phase I study is being conducted in late-stage, …
Share

19 November
Ziopharm Oncology Announces Data Highlighting Gene Therapy Approach in Glioma

BOSTON, Nov. 19, 2015 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the Company is presenting initial results from an ongoing Phase 1 dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or grade III malignant …
Share

17 April
Oncolytics’ Reolysin Receives Orphan Drug Designation for Malignant Glioma

US health regulators granted orphan drug designation to Calgary-based Oncolytics Biotech’s lead brain tumor candidate. The company announced that the US Food and Drug Administration (FDA) granted orphan status to its Reolysin for treatment of malignant glioma. Oncolytics said that it had applied for orphan designation for pediatric high grade …
Share

22 January
Hormonal Contraceptives Linked to an Increased Risk of Rare Brain Cancer

Long-term use of contraceptive pills may double the risk of developing brain cancer, according to a new study. Scientists say that taking hormonal contraception, particularly progesterone-only methods, for five years more than doubles the chance of developing glioma, a rare type of brain cancer which affects roughly five in 100,000 …
Share